AU1466399A - N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6 -dihydro-1-pyrimidinyl)aceto- xyl)-l-aspartic acid aldehyde as an (in vivo) inhibitor of interleukin-1beta converting enzyme (ice) - Google Patents

N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6 -dihydro-1-pyrimidinyl)aceto- xyl)-l-aspartic acid aldehyde as an (in vivo) inhibitor of interleukin-1beta converting enzyme (ice)

Info

Publication number
AU1466399A
AU1466399A AU14663/99A AU1466399A AU1466399A AU 1466399 A AU1466399 A AU 1466399A AU 14663/99 A AU14663/99 A AU 14663/99A AU 1466399 A AU1466399 A AU 1466399A AU 1466399 A AU1466399 A AU 1466399A
Authority
AU
Australia
Prior art keywords
interleukin
converting enzyme
inhibitor
xyl
aceto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14663/99A
Other languages
English (en)
Inventor
Gerald Paul Schielke
Aurash Shahripour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Warner Lambert Co LLC
Original Assignee
BASF SE
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE, Warner Lambert Co LLC filed Critical BASF SE
Publication of AU1466399A publication Critical patent/AU1466399A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU14663/99A 1998-01-20 1998-11-20 N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6 -dihydro-1-pyrimidinyl)aceto- xyl)-l-aspartic acid aldehyde as an (in vivo) inhibitor of interleukin-1beta converting enzyme (ice) Abandoned AU1466399A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7191898P 1998-01-20 1998-01-20
US60071918 1998-01-20
PCT/US1998/024848 WO1999036426A1 (en) 1998-01-20 1998-11-20 N-[2-(5-BENZYLOXYCARBONYL-AMINO-6-OXO-2-(4-FLUOROPHENYL)-1,6-DIHYDRO-1-PYRIMIDINYL)ACETO- XYL]-L-ASPARTIC ACID ALDEHYDE AS AN IN VIVO INHIBITOR OF INTERLEUKIN-1β CONVERTING ENZYME (ICE)

Publications (1)

Publication Number Publication Date
AU1466399A true AU1466399A (en) 1999-08-02

Family

ID=22104428

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14663/99A Abandoned AU1466399A (en) 1998-01-20 1998-11-20 N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6 -dihydro-1-pyrimidinyl)aceto- xyl)-l-aspartic acid aldehyde as an (in vivo) inhibitor of interleukin-1beta converting enzyme (ice)

Country Status (11)

Country Link
EP (1) EP1049703B1 (enExample)
JP (1) JP2002509153A (enExample)
AT (1) ATE232536T1 (enExample)
AU (1) AU1466399A (enExample)
CA (1) CA2309546A1 (enExample)
DE (1) DE69811404T2 (enExample)
DK (1) DK1049703T3 (enExample)
ES (1) ES2193589T3 (enExample)
PT (1) PT1049703E (enExample)
WO (1) WO1999036426A1 (enExample)
ZA (1) ZA99369B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2001243598A1 (en) 2000-03-13 2001-09-24 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
JP2004505014A (ja) 2000-04-05 2004-02-19 ファルマシア・コーポレーション 凝血カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換された4−ピロン類
US6693121B2 (en) 2000-04-05 2004-02-17 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
AU2001222501A1 (en) * 2000-05-18 2001-11-26 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2001280590A1 (en) * 2000-07-18 2002-01-30 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
WO2002042272A2 (en) 2000-11-20 2002-05-30 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
ES2675735T3 (es) 2001-06-26 2018-07-12 Amgen Inc. Anticuerpos para OPGL
EP1432687A2 (en) 2001-10-03 2004-06-30 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
NZ605429A (en) 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
KR101135765B1 (ko) 2004-03-12 2012-04-23 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
US20060128696A1 (en) 2004-05-15 2006-06-15 Annamaria Vezzani Treating seizures using ice inhibitors
JP2008500374A (ja) 2004-05-27 2008-01-10 バーテックス ファーマシューティカルズ インコーポレイテッド 自己炎症性疾患の処置のためのiceインヒビター
CA2616337A1 (en) 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
EP2635907A4 (en) 2010-11-05 2014-04-16 Univ Brandeis ICE-COLDED ALPHA SYNNUCLEINE A BIOMARKERS
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
NZ283876A (en) * 1994-03-31 2001-03-30 Vertex Pharma Pyrimidinyl derivatives as interleukin inhibitors

Also Published As

Publication number Publication date
EP1049703A1 (en) 2000-11-08
WO1999036426A1 (en) 1999-07-22
CA2309546A1 (en) 1999-07-22
ES2193589T3 (es) 2003-11-01
DE69811404T2 (de) 2003-12-04
DK1049703T3 (da) 2003-06-02
PT1049703E (pt) 2003-06-30
ATE232536T1 (de) 2003-02-15
EP1049703B1 (en) 2003-02-12
ZA99369B (en) 1999-07-20
JP2002509153A (ja) 2002-03-26
DE69811404D1 (de) 2003-03-20

Similar Documents

Publication Publication Date Title
AU1466399A (en) N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6 -dihydro-1-pyrimidinyl)aceto- xyl)-l-aspartic acid aldehyde as an (in vivo) inhibitor of interleukin-1beta converting enzyme (ice)
NO991674L (no) Interleukin-1<Beta>omdannelsesenzym-inhibitor-sulfonamider
CA2186511A1 (en) Pyrimidinyl derivatives as interleukin inhibitors
CA2338220A1 (en) Substituted imidazoles having cytokine inhibitory activity
EP1034164A4 (en) BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS
EP2011800A3 (en) Inhibitors of caspase
NZ326610A (en) Inhibitors of interleukin-1B or beta converting enzyme and use thereof
WO1998024804A3 (en) INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).
AU4817297A (en) Sulfonamide substituted aspartic acid interleukin-1beta converting enzyme inhibitors
YU67900A (sh) Sukcinamidni inhibitori interleukin-1beta konvertujućeg enzima
ITMI940419A0 (it) Procedimento per il trattamento di rifiuti solidi urbani, nonche' impianto per la sua realizzazione
MX9805015A (es) INHIBIDORES DE LA ENZIMA QUE CONVIERTE LA INTERLEUCINA-1 beta.
SI1049703T1 (en) N-(2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-fluorophenyl)-1,6-dihydro-1-pyrimidinyl)acetoxyl)-l-aspartic acid aldehyde as an in vivo inhibitor of interleukin-1beta converting enzyme

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase